Skip to main content
About Croma – Press & Downloads – Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
IMG 2489 1

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast

We’re proud to announce that Novaestiq Corp., a joint venture of Croma-Pharma and Gore Range Capital, is now part of Waldencast. This marks a major step in our global growth strategy. 

Our innovative Saypha® ChIQ™ and MagIQ™ HA injectables will launch in the U.S. under the Obagi Medical brand—backed by world-class science, high safety standards, and a legacy of over 110 million syringes produced across 80+ markets.

This partnership accelerates our mission to deliver high-quality, minimally invasive aesthetic solutions worldwide.

Downloads

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast (58 KB)
Back to top

If you are a healthcare professional (HCP), please log in to see specific information about our products.

Login

I've lost my password

Registration

* fields are required

This website uses cookies

We use cookies to personalise content, to provide social media features and to analyse our traffic. We also share information about your use of our website with our social media and analytics partners, which they may combine with other information you have provided to them or that they have collected from your use of their services. You consent to our cookies if you continue to use our website.